Furthermore, reduced miR-16-5p, miR-9-5p, and miR-195 enhanced breast cancer cell proliferation, and accelerated the cell cycle by targeting AKT3 (65), androgen receptor signaling (66), and cyclin E1 (CCNE1) (67), respectively. Here, AKT3 is linked to breast carcinoma.